Clinical Trial Details
— Status: Terminated
Administrative data
| NCT number |
NCT02878694 |
| Other study ID # |
2015-001192-48 |
| Secondary ID |
|
| Status |
Terminated |
| Phase |
Phase 2/Phase 3
|
| First received |
|
| Last updated |
|
| Start date |
November 14, 2019 |
| Est. completion date |
October 9, 2020 |
Study information
| Verified date |
November 2020 |
| Source |
University Hospital, Caen |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Interventional , multicenter , comparative study. One eye receiving the cells and the
contralateral eye as a negative control . If effectiveness following review of the primary
endpoint and the advice of an independent expert committee , the experimental treatment will
be offered to the patient to the contralateral eyelid.
Objective is to restore muscle function levator muscle of the upper eyelid by providing a
registry of autologous myoblasts from a non- clinically affected muscle .
Description:
Muscular dystrophy oculopharyngeal ( OPMD ) is an autosomal dominant inherited myopathy
manifested as selective involvement of the levator muscles of the upper eyelids , head of
ptosis, and muscles of the intersection pharyngolaryngeal originally disorders swallowing.
Ptosis can be treated with surgery ( shortening of the levator muscle ), but the disease
continues to evolve , relapses occur , necessitating another intervention , which is the
suspension of the eyelid to the frontal muscle that can cause corneal complications by
imperfect lid closure .
Main objective is to restore muscle function levator muscle of the upper eyelid by providing
a registry of autologous myoblasts from a non- clinically affected muscle .
A study on the same model was conducted in patients in ENT OPMD crossroads of muscles with
encouraging results , 12/12 patients had improved quality of life and no degradation of
swallowing was observed in 10 / 12 patients.
This is an interventional study , multicenter, comparative , one eye receiving the cells and
the contralateral eye as a negative control . If effectiveness following review of the
primary endpoint and the advice of an independent expert committee , the experimental
treatment will be offered to the patient to the contralateral eyelid.
Seven centers are associated with this project as inclusion and assessment center. Patients
are referred by different clinical sites in Caen ophthalmology department which will be
performed pre-transplant assessment, the collection of donor myoblast muscle graft and part
tracking.
The expected duration is 3 years (2 years of inclusion and evaluation of the primary endpoint
at 1 year) for inclusion of 10 patients.
The safety of autologous myoblast transplantation has been shown in several directions with
promising efficacy results. They will be produced by the unit of Biotherapy Rouen University
Hospital (Prof. O. Boyer), who currently leads a test with these cells (ClinicalTrials.gov,
myoblast for Anal Incontinence (MIAS), NCT01523522, 24 patients were provided in Protocol was
included in July 2014, at 6 months follow up of the last patient is expected in January 2015)
and authorized the production of advanced therapy medicinal products prepared punctually
(ANSM).
In this study, different successive steps:
- Step of including: patient aged 18 to 75, verification of the diagnosis of the disease,
evaluation balance ptosis (measurements, photographs, films), obtaining consent,
- Muscle biopsy of a healthy muscle to cell amplification, an outpatient basis, under
local anesthesia, 3 to 4 weeks before transplantation,
- Transplant myoblasts by multiple intramuscular injections (6), under local anesthesia.
Longitudinal microscarifications be made superficially injected into muscles to
stimulate muscle regeneration. Intramuscular injection of myoblasts will be in the
levator muscle of the upper lid 6 in equidistant points, each injection containing 5
million cells. These injections will be made in muscle mass over an area of about 5 cm2,
ranging between 6 and 20 mm above the tarsus to be in the thick muscle area. It is
intended to be injected into the eye to treat randomized a total of 30 million
myoblasts. This protocol is based on the one used for correction of ENT disorders within
several PHRC under the responsibility of Professor Sophie Périé. The doses used for the
myoblast transplantation in the pharyngeal constrictor muscles were adapted to the
levator muscle of the eyelid.
- Follow-up visits for 3 years for each patient:
- The first year, to evaluation of the primary endpoint visit to 8 days to a month,
then every 3 months
- Out protocol and up to 3 years after administration of the cells every 6 months
(this monitoring will be carried out as part of standard care).
These visits evaluate the effectiveness of the transplant on different objective measurements
on both eyes (eyelid opening slot in the gaze straight ahead; levator muscle strength of the
upper eyelid, visual benefit: measurement of visual acuity measurement visual field), and the
profit on neck pain. The tours include a side effect detection examination (local
inflammatory phenomena, palpable lumps).
In the end, this landmark trial for the new F.H.U. SURFACE dealing with regenerative medicine
in the head and neck, the investigators expect an improvement in the quality of the levator
of the upper eyelid muscles deficient with a correction of ptosis in patients.
